Introduction

In the complex landscape of clinical trials, precision is paramount. A recurring challenge in trial design and analysis has been the misalignment between the clinical question posed and the statistical analysis performed. This disconnect often stems from how we handle intercurrent events — events like treatment discontinuation or the use of rescue medication that occur after randomization and affect the interpretation of the outcome.

The ICH addressed this critical gap with the E9(R1) Addendum to Statistical Principles for Clinical Trials. This guidance introduces a structured framework centered on "estimands."

The Purpose of E9(R1)

The primary goal of the E9(R1) Addendum is to improve transparency and alignment in clinical trials. Before this guidance, protocols often vaguely defined "intention-to-treat" (ITT) principles without explicitly stating how to handle data affected by intercurrent events. The Addendum mandates a disciplined process to define exactly what needs to be estimated before determining how to estimate it, requiring cross-functional collaboration between clinicians and statisticians early in the study design phase.

Key Components: The Estimand Framework

An estimand is a precise description of the treatment effect that is to be estimated. The E9(R1) framework breaks an estimand down into five essential attributes:

1. The Treatment — Defines exactly what the experimental treatment and control treatment involve, including the entire treatment regimen.

2. The Population — Defines the group of patients targeted by the clinical question.

3. The Variable — The specific endpoint to be obtained for each patient, including the type of variable and timing of assessment.

4. Intercurrent Events — The most transformative aspect. The protocol must list potential intercurrent events and explicitly state how each will be handled. The guidance offers five strategies:

• Treatment Policy Strategy: The occurrence of the intercurrent event is irrelevant; data are used regardless (consistent with ITT)

• Composite Variable Strategy: The intercurrent event is integrated into the endpoint itself

• Hypothetical Strategy: Estimate the effect in a scenario where the intercurrent event would not occur

• Principal Stratum Strategy: Estimate the effect only in the sub-population who would not experience the intercurrent event

• While on Treatment Strategy: Assess the response prior to occurrence of the intercurrent event

5. Population-Level Summary — Defines how the variable will be summarized to compare treatment groups (e.g., difference in means, hazard ratio, odds ratio).

Impact on Trial Design and Conduct

The framework demands that the estimand be defined in the protocol before the statistical analysis plan is written, requiring cross-functional collaboration. Once strategies for intercurrent events are chosen, they dictate data collection requirements. The framework also highlights the distinction between "missing data" and data that are simply not relevant due to an intercurrent event.

Real-World Application: A Diabetes Trial Example

Consider a clinical trial for a Type 2 diabetes medication comparing a new drug to placebo, with primary endpoint of change in HbA1c at Week 24. Patients may require rescue medication if blood sugar becomes dangerously high.

• Treatment Policy Strategy: Use the HbA1c at Week 24 as observed, regardless of whether rescue medication was used. Reflects a "real-world" effectiveness perspective.

• Composite Strategy: A patient is a "responder" only if they achieve the HbA1c target AND do not require rescue medication. Changes the variable from continuous to binary, fundamentally changing the sample size calculation.

• Hypothetical Strategy: Censor data collected after rescue medication initiation and use statistical modeling to predict what HbA1c would have been without rescue medication. Relies heavily on statistical assumptions that must be rigorously justified.

Sensitivity Analysis: Ensuring Robustness

The E9(R1) Addendum emphasizes that the main estimator must be validated through sensitivity analysis. Sensitivity analysis tests whether results hold up under different assumptions. If the treatment effect remains significant across these different assumptions, the results are considered robust — proving the positive outcome is not merely an artifact of a specific statistical method.

Conclusion

The E9(R1) Addendum is more than a regulatory requirement; it is a tool for strategic alignment. By rigorously defining estimands, sponsors can ensure that their trials are designed to answer the right questions with precision and clarity, minimizing the risk of regulatory setbacks.

Next Steps:

• Review your current protocols to ensure clear estimand definitions are in place

• Engage your biostatistics and clinical teams early in the design process to discuss intercurrent events

• Consult with regulatory experts to align your chosen strategies with agency expectations for your specific therapeutic area